Uloric febuxostat: Phase III data

The 6-month, double-blind Phase III CONFIRMS trial in 2,269 patients showed that daily febuxostat met the primary endpoint of proportion of patients with a serum rate level of <6.0 mg/dL at the final visit. High-dose febuxostat (80 mg) was superior to both low-dose febuxostat (40 mg) and allopurinol (67.1% vs. 45.2% and 42.1%, p<0.001 for both). Low-dose febuxostat was non-inferior to allopurinol. In patients with moderate renal impairment, low-dose febuxostat had a significantly higher response rate vs. allopurinol (p<0.05). Data were presented at the American College of Rheumatology meeting in Philadelphia. ...